第二节儿童急性非淋巴细胞白血病儿童急性非淋巴细胞白血病（acutenonlymphocyticleukemiaAML）约占儿童白血病的15%～20%，随着生物分子学的进展，对AML的发病机制及生物学特性有了更进一步的了解，目前在合理治疗后约有30%～45%的患儿可获得长期无病生存，较急性淋巴细胞白血病（ALL）的预后仍然明显差。
O O O B-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis B-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis O B-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis O O O B-dis I-dis I-dis I-dis I-dis O O O O O O O O O O O O O O O O O O O O O B-dis I-dis I-dis O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis I-dis O B-dis I-dis I-dis O O O O O O O O O O